Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Neurology antibodies target proteins involved in neurodegeneration, neuropathic pain and migraine signaling. Aducanumab, gantenerumab and donanemab bind aggregated forms of amyloid beta (Aβ), each with a different preference for oligomers, fibrils or plaque species. Fremanezumab and galcanezumab neutralize calcitonin gene-related peptide (CGRP), whereas erenumab blocks the CGRP receptor. Tanezumab neutralizes nerve growth factor (NGF), a key mediator of nociceptor sensitization in inflammatory pain models. Further antibodies bind tau, alpha-synuclein and axon-growth inhibitors such as myelin-associated glycoprotein and repulsive guidance molecule A.
Povovetug is a humanized IgG1κ chimeric monoclonal antibody that specifically targets nerve growth factor (NGF) and brain-derived nerve growth factor (bNGF). This antibody exhibits potent analgesic activity, making it a valuable tool for research into central neuroinflammation. Povovetug is particularly relevant for studies investigating chronic radicular pain and related pain mechanisms.
Out of stock
All 3 sizes
Synonyms: RG6102; RO-7126209
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1.
MEDI-578 is a CHO-expressed human monoclonal antibody that targets nerve growth factor (NGF), including its biologically active β-subunit (β-NGF). Featuring a human IgG2a heavy chain and lambda light chain, MEDI-578 is suitable for preclinical research into pain signaling, neurotrophin biology, and inflammation-related disorders. Recommended isotype control: Human IgG4 kappa isotype control.
Nadecnemab is an IgG4κ monoclonal antibody that targets GDNF family receptor alpha 3 (GFRA3), a receptor involved in neurotrophic signaling. Nadecnemab is suitable for research into chronic pain and osteoarthritis of the knee, particularly in models examining the GDNF–RET signaling axis.
Synonyms: LY3372993
Remternetug is a human monoclonal antibody of the immunoglobulin G1-kappa class, designed to target the N3pGlu-modified peptide of amyloid beta (Aβ42), a key component in amyloid plaque formation associated with Alzheimer's disease. This antibody specifically recognizes the pyroglutamate form of Aβ, a post-translationally modified version implicated in the disease's pathology. Studies have demonstrated that Remternetug facilitates a rapid and substantial reduction in amyloid plaque deposition, making it an invaluable tool for research into the pathogenesis and potential therapeutic interventions of Alzheimer's disease.
The Anti-NGF/bNGF Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target nerve growth factor (NGF) and its precursor form, proNGF (bNGF). This antibody features a human IgG2a heavy chain and a human kappa light chain, with a predicted molecular weight of 144.14 kDa. For experimental control purposes, the Human IgG2 kappa, Isotype Control is recommended. This antibody is essential for research focused on the role of NGF in pain, inflammation, and neurodegenerative diseases, providing a valuable tool for both therapeutic and basic science investigations.
Sabirnetug is a humanized IgG2κ monoclonal antibody specifically designed to target the Amyloid-β A4 precursor protein. This antibody is engineered for high specificity and affinity, making it an ideal tool for research focused on Alzheimer's disease and other amyloid-related disorders.
Synonyms: GSK249320
Refanezumab (GSK249320) is a humanized IgG1 monoclonal antibody targeting myelin-associated glycoprotein (MAG). This antibody specifically binds to MAG, thereby inhibiting its role in suppressing axonal regeneration. Demonstrating the ability to traverse the blood-brain barrier in animal models of stroke, Refanezumab offers promising potential for facilitating functional recovery following stroke events. This therapeutic candidate is pivotal for research focused on neural repair and neuroregenerative pathways.
Synonyms: JNJ-63733657
Posdinemab is a humanized IgG1κ monoclonal antibody designed to specifically target the microtubule-associated protein tau (MAPT). This antibody is engineered for high specificity and affinity in recognizing and binding to the tau protein, which is implicated in neurodegenerative disorders such as Alzheimer's disease. Posdinemab is utilized in research focused on the pathology and therapeutic interventions of tau-related diseases.
Synonyms: PF-04360365; RN 1219
Ponezumab (PF-04360365) is a humanized IgG2 monoclonal antibody designed to target and reduce amyloid beta (Aβ) levels in the central nervous system. Demonstrating efficacy in preclinical studies, Ponezumab has shown to enhance cognitive performance in mouse models across various learning and memory paradigms. This antibody is particularly valuable for research focused on the pathophysiology and potential treatments for Alzheimer's disease.
Synonyms: BIIB054; Anti-Alpha-synuclein Reference Antibody (cinpanemab
Cinpanemab (BIIB054) is a human-derived monoclonal antibody specifically designed to target α-synuclein. This antibody has significant applications in the research of Parkinson's disease, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions targeting α-synuclein aggregation.
GSK-933776 is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting Amyloid Beta (Aβ). This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with a predicted molecular weight of 145.34 kDa. For experimental control purposes, the appropriate isotype control is Human IgG1 kappa. GSK-933776 is relevant for research into Alzheimer's disease and other amyloid-related disorders, providing a valuable tool for the investigation of amyloid beta dynamics and pathology.
Amdokitug is a human IgG1 λ monoclonal antibody targeting MUSK. For control experiments, it is recommended to use Human IgG1 Lambda2 as an isotype control.
Eptinezumab is a humanized monoclonal antibody designed to selectively bind to calcitonin gene-related peptide (CGRP), effectively inhibiting its interaction with its receptor. This blockade of CGRP, a neuropeptide involved in migraine pathogenesis, makes eptinezumab an effective preventive treatment for migraine in adults. Its targeted mechanism of action positions it as a critical tool for research in neurology and headache disorders.
Synonyms: BIIB033
Opicinumab (BIIB033) is a monoclonal antibody specifically targeting LINGO-1, a protein implicated in the inhibition of axonal regeneration and myelination. This antibody is under investigation for its potential therapeutic applications in treating acute optic neuritis as well as relapsing forms of multiple sclerosis, aiming to enhance neuronal repair and improve neurological function.
Synonyms: TEV-48125
Fremanezumab (TEV-48125) is a humanized IgG2a monoclonal antibody designed for high specificity and potency in binding to calcitonin gene-related peptide (CGRP). CGRP, a 37-amino acid neuropeptide, plays a critical role in the central and peripheral mechanisms underlying migraine pathophysiology. This antibody is particularly relevant for research focused on chronic migraine, providing a valuable tool for elucidating the biological pathways involved in this condition.
Indenebart is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets SNCA (alpha-synuclein). For accurate experimental control, it is recommended to use Human IgG1 lambda2 as an isotype control. This antibody is ideal for research focused on the pathological roles of alpha-synuclein, including its implications in neurodegenerative disorders such as Parkinson's disease.
Synonyms: PRX 002; RG 7935; RO 7046015
Prasinezumab (PRX 002) is a humanized IgG1 monoclonal antibody that specifically targets aggregated α-synuclein. This antibody is designed for use in research related to Parkinson's disease, offering potential insights into disease mechanisms and therapeutic interventions.
Synonyms: ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody designed for high selectivity toward repulsive guidance molecule A (RGMa). This antibody effectively inhibits RGMa-mediated BMP signaling through the SMAD1/5/8 pathway, demonstrating a potent inhibitory concentration (IC50) of approximately 97 pM. Elezanumab binds to the N-terminal of RGMa, effectively blocking BMP signaling pathways and demonstrating no cross-reactivity with RGMc. It has been shown to promote both neuroregeneration and neuroprotection across various models of neuronal injury and demyelination. Importantly, Elezanumab exerts its neuroregenerative and neuroprotective effects without affecting iron metabolism, making it a targeted therapeutic option for neurological research and potential clinical applications.
Synonyms: MABT 5102A; RG 7412
Crenezumab (MABT 5102A; RG 7412) is a fully humanized monoclonal antibody designed to target and bind various forms of amyloid beta (Aβ), including soluble, oligomeric, and fibrillar aggregates. This antibody is extensively utilized in the study of Alzheimer's disease, providing a critical tool for researchers investigating the pathogenesis and potential therapeutic interventions for this neurodegenerative disorder.
MEDI-1814 is a fully human IgG1 monoclonal antibody designed to target the C-terminus of amyloid beta (Aβ) 42 peptide. This antibody specifically binds to circulating Aβ peptides, facilitating their removal and preventing their aggregation into neurotoxic oligomers. MEDI-1814 is primarily utilized in research focused on the pathogenesis and potential treatments of Alzheimer's disease. For experimental control purposes, the Human IgG1 kappa, Isotype Control is recommended.
Gantenerumab is a fully humanized IgG1 monoclonal antibody designed to target amyloid-beta (Aβ) fibrils and plaques, which are hallmark features in the pathology of Alzheimer's disease. This antibody exhibits high specificity for Aβ aggregates, making it an essential tool for research focused on the mechanisms and therapeutic interventions of Alzheimer's disease. Gantenerumab is particularly valuable in studies aiming to understand the role of amyloid plaques in neurodegeneration and as a potential therapeutic agent in clinical settings.
Synonyms: NV-01
Ranevetmab (NV-01) is a caninized monoclonal antibody targeting nerve growth factor (NGF). This antibody is specifically engineered for use in canine models to investigate and alleviate pain associated with degenerative joint disease (DJD). Ranevetmab binds selectively to NGF, a key mediator in the pathway of pain, thereby inhibiting its activity and providing a valuable tool for research into novel pain therapies in veterinary medicine.
Synonyms: GSK1223249
Ozanezumab (GSK1223249) is a monoclonal antibody targeting Nogo-A, a protein known to inhibit neurite outgrowth. This antibody is primarily utilized in the study of neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), providing a valuable tool for exploring the mechanisms underlying these diseases and potential therapeutic approaches.
